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Uterine cancer is the most common pelvic gynecological malignancy. Uterine 
sarcomas and relapsed uterine carcinomas have limited treatment options. The 
search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much 
promise, though has been poorly explored in uterine cancer. This commentary gives 
an insight in existing DC immunotherapy studies in uterine cancer and summarizes 
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the possibilities and the importance of the loading of tumor antigens onto DC and 
their subsequent maturation. However, the sole application of DC immunotherapy to 
target uterine cancer will be insufficient because of tumor-induced 
immunosuppression, which willhamper the establishment of an effective anti-tumor 
immune response. The authors give an overview on the limited existing 
immunosuppressive data and propose a novel approach on DC immunotherapy in 
uterine cancer. 
Introduction 
Worldwide, uterine cancer is the seventh most common malignant disorder and the 
most frequent pelvic gynecological cancer. Each year, in Europe, an estimated 9000 women 
die of the disease. It occurs mainly in postmenopausal women with a mean age of 65 y. 
Uterine tumors can be epithelial or mesenchymal in origin and are designated as 
carcinoma and sarcoma, respectively. While sarcomas are uncommon but most of the time 
highly aggressive, uterine carcinomas comprise the majority of cancer cases of the corpus 
uteri, but normally have a lower grade malignancy potential.More than 73% of the patients 
with the most frequent subtype of endometrial cancer present at FIGO stage I, resulting in a 5-
y survival of 85 to 90%. However, more rare subtypes of endometrial carcinoma as well as 
uterine sarcoma display a more aggressive behavior and thus often present in more advanced 
stages with a 5-y survival of 5–20%, depending on the subtype. Surgery is the cornerstone of 
treatment. The value of adjuvant chemotherapy is controversial for carcinoma and proven not 
beneficial for high grade uterine sarcoma. In advanced or recurrent disease, treatment options 
are strongly limited.1,2Therefore, there is an urgent need for exploration of new treatment 
options for uterine tumors. 
One type of active immunotherapy is dendritic cell (DC) immunotherapy.DC have 
been discovered in 1973 by Ralph Steinman and since then, their role as sentinels of the 
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immune system that provide an essential link between innate and adaptive immunity has been 
elucidated. DC comprise only a minor (<1%) subset of the white blood cell population. 
Immature dendritic cells have the capacity to capture and process antigens, a process which 
leads to their maturation. Through interaction of the chemokine receptor CCR7 and its ligands 
CCL19/CCL21 DC migrate to the lymph nodes, where the processed antigens are presented to 
T cells, thus initiating an immune response.3 Since the isolation of circulating DCs is 
challenging, DC immunotherapy is most frequently based on DCs cultured in an ex vivo 
setting starting from CD34+ precursor cells or CD14+monocytes. At the immature state DC 
are loaded with (defined) tumor antigens, offered as synthetic peptides or mRNA. 
The application of active immunotherapy in the treatment of uterine cancer has not 
been explored for a long time and is still in its infancy, which is probably related to the poor 
insight into the interaction of the immune system with uterine cancers. However, as our 
knowledge increases, we believe that immunotherapeutic approaches hold promise for uterine 
cancer.Active immunotherapy relies on anticancer vaccines that are able to elicit an immune 
response against tumor-associated antigens (TAAs) in the human body. Table 1 gives an 
overview of existing studies. 
Loading of Tumor Antigens 
Immunotherapeutic targets can consist of one or more defined TAA or a tumor-
derived mixture of unknown TAA. Several TAA are validated for immunotherapy in uterine 
tumors such as for example several cancer testis antigens,8 MUC1,9 universal TAA such as 
hTERT or antigens targeting tumor cell survival such as survivin (Vanderstraeten et al., 
unpublished data). Until now the majority of antigen-focused immunotherapeutic studies in 
general have used a single antigen as a target. However, more and more arguments are arising 
for settings using a combination of multiple antigens or the use of total tumor cell approach. 
There are 3 major advantages. First of all, by using a combination of several antigens, the risk 
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of immune escape is reduced. Second, by using multiple antigens, the group of tumors and 
hence the patient group that can be targeted with one treatment approach is much larger. 
Lastly, by including anti-apoptosis factors as a target, the survival of the tumor itself can be 
attacked as well. Nevertheless, the use of a total tumor cell approach (tumor lysate, total 
tumoral mRNA,…) can theoretically induce auto-immunity, even though a certain amount of 
autoimmunity is necessary for efficient tumor eradication. To date, no reports of this type of 
side-effects have been published in the context of uterine cancer. 
A crucial component in any DC vaccine is the choice of the DC loading strategy. 
Immunotherapy usingDC loaded with peptide(s)is easily feasiblebut has several 
disadvantages, such as HLA restriction, the lack of a broad repertoire of MHC class II binding 
peptides and a short duration of antigen presentation. The in vitro work of several research 
groupshas suggested that RNA transfection of TAA is an effective, if not superior, method to 
generate immunostimulatory DCs. By using mRNA encoding the whole TAA, RNA 
transfectionis independent of the patients HLA-type.10,11In addition, further modification of 
the coding sequence by adding lysosomal targeting sequences (e.g., DC-LAMP) leads to the 
presentation of antigenic peptides in the context of both HLA class I and class II.12-14 
Our research group has proven the safety and feasibility of DC immunotherapy in 
large series of high-grade glioblastoma (DCs loaded with lysate)15 and in case reports of 
uterine and ovarian tumors (WT1 mRNA-loaded DCs).5,6,16 
Maturation Status of DC 
DC vaccines should be able to induce high avidity CD8+ T cells that express high 
levels of granzyme and perforin and are able to enter the tumor microenvironment to exert 
their function. The quality of the induced CD8+ T cells is influenced by the expression of co-
stimulatory molecules, such as CD80, CD86, CD137, and CD252 on DC, the cytokine 
secretion pattern of DC and the type of CD4+ helper T cell response.17-19DC maturation is one 
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of the crucial factors.20,21 Currently, the “golden standard” used to mature DC consists of a 
cocktail of pro-inflammatory cytokines (IL-1β, IL-6, TNFα) and prostaglandin E2.22However, 
a whole scale of cytokines, all mimicking the in vivo danger signal, is available to mature DC, 
such as IRX-2and CD137.23,24Recent mouse data demonstrated, however, that maturation of 
DC solely by pro-inflammatory cytokines yielded DC that failed to efficiently direct effector 
T cell differentiation. Interestingly, DC matured in the presence of Toll like receptor (TLR) 
ligands were able to induce full T cell effector function and induce more potent immune 
responses.25,26 
More recent in the field of DC maturation is the use of TriMixco-electroporation 
(caTLR4 [constitutively active Toll-like receptor 4], CD40L, and CD70 mRNA). The 
combination of CD40L and caTLR4 electroporation mimics CD40 ligation27,28 and TLR4 
signaling29 of the DC and generates phenotypically mature, cytokine/chemokine-secreting 
DC, as has been shown for CD40 and TLR4 ligation through addition of soluble CD40L and 
lipopolysaccharide (LPS).30 On the other hand, the introduction of CD70 into the DC provides 
a co-stimulatory signal to CD27+ naive T cells by inhibiting activation-induced cell death 
(AICD) of T cells and by supporting T cell proliferation.31DC co-electroporated with TriMix 
and tumor antigens have been shown to be potent stimulators of anti-tumor immunity in 
melanoma patients.32-35Providing the DCs with a maturation signal through mRNA 
electroporation offers several advantages. There is no need to pre-incubate the DCs for up to 
48 h with soluble maturation signals like pro-inflammatory cytokines or TLR ligands to 
achieve DC activation, which can render the cells “exhausted” and inferior for vaccination 
purposes.36 As a result, TriMix DC, which can be injected into the patient within a short 
period after electroporation, will mature and secrete most of their immunostimulatory 
cytokines and chemokinesin situ. Furthermore, it has been postulated that maturation of DCs 
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in situ resembles more closely the physiologic process involved in response to pathogen 
infection and may therefore lead to enhanced T-cell immunity.37 
Tumor Microenvironment 
The sole application of DC immunotherapy to target uterine cancer is, however, not 
sufficient because of tumor-induced immunosuppression. More and more attention is being 
brought to the infiltrationof immune suppressive cells in the tumor microenvironment as a 
response to classical treatments and immunotherapeutic strategies. These immune suppressive 
cells hamper the establishment of an effective anti-tumor immune response. To our 
knowledge, this has been poorly studied in uterine cancer and results are often contradictory. 
The role of tumor-associated macrophages (TAMs) in endometrial carcinoma is 
complex. Located in close contact with cancer cells, they have a beneficial effect on relapse-
free survival, but TAMs located in necrotic tumor tissue are linked with tumor recurrence.38 
Moreover, TAMs secrete matrix metalloproteinases and induce angiogenesis which promote 
tumor progression.39Furthermore, TAMs are associated with myometrial invasion and lymph 
node metastasis and thus have a clear tumor-promoting role.40,41 
Endometrial tumors are frequently infiltrated by T lymphocytes as well. CD8+ 
lymphocytes present in primary untreated stage IA-IIIA endometrial cancer, show 
upregulation of inhibitory natural killer receptors, an effect that possibly is mediated through 
TGF-β. However, this upregulation prevents the cytotoxic function of these lymphocytes at 
the HLA recognition level, thus causing an important tumor evasion strategy, since non-
classical HLA molecules are upregulated in cancer.42A recent publication showed the 
association of uterine sarcoma with systemic inflammation, as measured by an enhanced 
neutrophil to lymphocyte ratio in these patients.43Tumor-infiltrating lymphocytes (TIL) can be 
detected in uterine sarcoma, but these cells can sometimes harbor chromosomal aberrations 
which might negatively impact their functionality.44 
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In many tumors, regulatory T cells (Treg) suppress endogenous and induced antitumor 
immune responses. However, in endometrial carcinoma, the presence of Treg is debatable. 
Fattorossiet al.45 showed their presence in the tumor-draining lymph nodes of 26 patients, 
whereas Giatromanolakiet al.46 demonstrated less Treg in 79 stage I endometrial carcinoma 
patients compared with normal endometrium.Recent work of both Yamagamiet al.47 and 
Zhang et al.48 demonstrated an increase of Treg in the tumor tissue and peripheral blood 
respectively in endometrial carcinoma, increasing in more advanced stages. In contrast, the 
group of Sawanet al.49attributed this increase in Tregs to an increase in age and to the 
postmenopausal condition of most patients. 
More recently, myeloid derived suppressor cells (MDSC) have been shown to play an 
important role in cancer immunosuppression and have been implicated in several tumor types. 
We showed for the first time that both endometrial carcinoma and uterine sarcoma tumors 
contain MDSC infiltrates that express arginase-1.50 
Proof of Concept 
In order to improve our previous DC vaccination regimen, several modifications were 
incorporated: 
1) Inclusion of both WT1 and survivin as targets to broaden the immune response 
2) Inclusion of the DC-LAMP targeting signal in the WT1 and survivin mRNA for 
induction of both CD4+ and CD8+ T cells 
3) Co-electroporation of WT1 and survivin with TriMix to induce DC maturation. 
The feasibility of this approach was tested on leukapheresis products of 3 healthy 
donors. Monocytes were isolated by elutriation and cultured in CellGenix culture bags in the 
presence of GM-CSF and IL-4 (Cellgenix) until day 7. Immature DC were harvested, 
electroporated with mRNA encoding WT1-DC.LAMP and TriMix or survivin-DC.LAMP and 
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TriMix, mixed and cultured for 3.5 to 4 h in the presence of rapamycin (MiltenyiBiotec 
Leiden), IL-4, and GM-CSFbefore cryopreservation. 
Upon thawing, DC showed a viability of 57.3 ± 5.5% and a purity of 64.6 ± 7.8%. DC 
phenotype was analyzed after thawing (4h after electroporation) and after an additional 44h 
culture period (48h after electroporation). Immediately after thawing, DC still presented with 
a rather immature phenotype, but became fully mature at 48h after electroporation, with 
upregulation of CD54, CD80, CD83, CD86, and CCR7 (Table 2). WT1 expression by DC 
was at the highest level 1.5 h after thawing and steadily decreased thereafter, while survivin 
only slightly decreased at 48h after thawing (Fig. 1). DC secreted low levels of IL-12p70, 
intermediate levels of IL-1β and IL-18 and high levels of IL-6, IL-8, MCP-1, and MIP-1α. 
Upon stimulation of autologous T cells, we observed an increase of survivin-tetramer 
(survivin 95–104 peptide) positive T cells from almost undetectable (0.08% of CD8+ T cells) 
to 0.56% of CD8+ T cells after 1 stimulation (7-fold) and to 0.81% of CD8+ T cells after 2 
stimulations with DC (10-fold). No induction of WT1-specific T cells was noted (Fig. 2). 
Conclusions 
DC immunotherapy is in its infancy in uterine cancer. Nevertheless, the recent data 
concerning the interaction of uterine tumors with the immune system indicate that 
immunotherapy is promising as a novel therapeutic approach for this type of cancer. 
Furthermore, immunotherapeutic approaches are associated with less toxicity and fewer side 
effects, which is important for an elderly patient population. We have previously shown the 
feasibility of DC vaccination in uterine cancer and we anticipate that our novel approach will 
further improve this modality. Moreover, in our opinion, the combination of DC vaccines with 
inhibitors of immunosuppression holds great promise for uterine cancer patients. 
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Figure 1.WT1 or survivin antigen expression by mRNA electroporated DC. DC electroporated with 
WT1.DC-LAMP + TriMix or survivin.DC-LAMP + TriMix were analyzed at 4h or 48h after 
electroporation for expression of WT1 or survivin by immunocytochemistry. The percentage of stained 
cells (left panel) and the intensity of staining (right panel) was documented. 
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Figure 2.Tetramer analysis of stimulated T cells. DC electroporated with WT1.DC-LAMP + TriMix or 
survivin.DC-LAMP + TriMix were used at 4h post electroporation to stimulate autologous T cells. 
Unstimulated T cells and stimulated T cells were stained for CD3, CD8, and the respective tetramer. 
Cells were gated on FSC/SSC characteristics and CD3+ CD8+ cells. On the CD3+ CD8+ T cells, the 
percentage of WT1- or survivin-tetramer positive cells was determined. 
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Table 1. Overview on DC immunotherapy in uterine cancer 
    
Group Tumor Number of Patients Type of Active Immunotherapy 
Santin A et al.4 
2002 
Serous 
endometrial 
carcinoma 
3 Injection of DCs loaded with whole tumor lysate 
Hernando JJ et al.5 
2002 
Uterine 
sarcoma 
2 Injection of DCs loaded with whole tumoral lysate and KLH 
Coosemans A et 
al.6 2010 
Serous 
endometrial 
carcinoma 
1 WT1-mRNA loaded DC immunotherapy 
Coosemans A et 
al.7 2013 
Leiomyosarco
ma and serous 
endometrial 
carcinoma 
6 WT1-mRNA loaded DC immunotherapy 
 
   
    
    
    
KLH, Keyhole Limpet Hemocyanin; WT1,Wilms’ tumor gene 1; DC: dendritic cell. 
 
 
Table 2. Characteristics of DC from 3 test leukaphereses (n = 3) 
   
   
Test 4 hours 48 hours 
Sterility   
bacteria negative negative 
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mycoplasm negative negative 
fungi negative negative 
endotoxins negative negative 
mDC-identity*   
CD11c 90.9% (12.7) 95.4% (2.2) 
CD14 11.8% (8.3) 5.3% (5.3) 
CD54 89.1% (11.8) 98.0% (3.7) 
CD80 38.1% (15.5) 98.3% (1.0) 
CD83 30.4% (8.0) 65.4% (9.0) 
CD86 76.7% (18.4) 98.3% (0.6) 
CCR7 25.8% (11.4) 96.5% (2.0) 
HLA-ABC 99.0% (0.6) 99.7% (0.2) 
HLA-DR 98.1% (2.2) 97.6% (2.1) 
mRNA 
electroporation* 
  
CD70 45.5% (11.8) 57.9% (22.8) 
Viability upon 
thawing* 
  
 
57.3% (5.5) 57.3% (5.5) 
Purity upon 
thawing* 
  
 
64.6% (7.8) 64.6% (7.8) 
 
*Results expressed as mean percentage (standard 
deviation). 
 
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
  
   
 
  
 
